Draft:Novogenia

Novogenia is a biotechnology firm that provides medical and lifestyle genetic tests, blood analysis services, personalized nutrition supplements, and cosmetics. In 2022, it was fined together with the ministry of health of Austria for illegal government grants. In 2021, Novogenia went public on the Munich stock exchange under its parent company Darwin AG.

History
Novogenia was founded in 2009 as a 20sqm laboratory by Wallerstorfer in Salzburg, Austria. The company shortly obtained a license from the Austrian government to conduct medical genetic testing and swiftly ventured into preventive genetic testing. In 2012, Novogenia acquired Genosense Diagnostics, an Austrian competitor based in Vienna. By 2013, the company achieved profitability.

In 2018, the company introduced Deep Genome AI, which uses artificial intelligence to interpret and store genetic research data, accelerating the development of gene-based products. In 2019, Novogenia's operations expanded significantly due to the COVID-19 crisis, emerging as Austria's largest COVID-19 laboratory, conducting up to 275,000 tests daily and producing millions of medical devices for sample collection.

On October 18, 2021, Novogenia founder Daniel Wallerstorfer was awarded "Entrepreneur of the Year" in the category of "Innovation & Hightech Rising Stars" in Salzburg.

In December 2021, Novogenia underwent an Initial Public Offering (IPO) on the Munich stock exchange under DARWIN AG, a biotechnology group of companies.

Activities
Novogenia's laboratory conducts genetic and blood analyses, producing personalized reports from these assessments. The laboratory handles a peak load of 275,000 samples daily and has conducted over 35 million PCR analyses. Also, the laboratory offers gene and allergy analyses, employing advanced analytical techniques like microfluidics and DNA microarrays. It captures up to 30 million genetic variations per sample and provides insights into nutrigenetics, performance enhancement, and skin genetics.